Trial
NCT03114319
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)
Intervention
TNO155
Why stopped
Business reasons and not due to any safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-16